参考文献/References:
[1] Sasset L,Zhang Y,Dunn TM,et al. Sphingolipid de novo biosynthesis:a rheostat of cardiovascular homeostasis[J]. Trends Endocrinol Metab,2016,27(11):807-819.
[2] Hannun YA,Obeid LM. Many ceramides[J]. J Biol Chem,2011,286(32):27855-27862.
[3] Yano M,Kishida E,Muneyuki Y,et al. Quantitative analysis of ceramide molecular species by high performance liquid chromatography[J]. J Lipid Res,1998,39(10):2091-2098.
[4] Wang P,Zeng G,Yan Y,et al. Disruption of adipocyte HIF-1α?improves atherosclerosis through the inhibition of ceramide generation[J]. Acta Pharm Sin B,2022,12(4):1899-1912.
[5] Choi RH,Tatum SM,Symons JD,et al. Ceramides and other sphingolipids as drivers of cardiovascular disease[J]. Nat Rev Cardiol,2021,18(10):701-711.
[6] Wang DD,Toledo E,Hruby A,et al. Plasma ceramides,Mediterranean diet,and incident cardiovascular disease in the PREDIMED trial (Prevención con Dieta Mediterránea)[J]. Circulation,2017,135(21):2028-2040.
[7] Meeusen JW,Donato LJ,Bryant SC,et al. Plasma ceramides[J]. Arterioscler Thromb Vasc Biol,2018,38(8):1933-1939.
[8] Cheng JM,Suoniemi M,Kardys I,et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome:results of the ATHEROREMO-IVUS study[J]. Atherosclerosis,2015,243(2):560-566.
[9] Mantovani A,Bonapace S,Lunardi G,et al. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography[J]. Diabetes Metab,2020,46(2):150-157.
[10] Mantovani A,Bonapace S,Lunardi G,et al. Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy[J]. Metabolism,2018,85:305-312.
[11] Kaasenbrood L,Boekholdt SM,van der Graaf Y,et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population[J]. Circulation,2016,134(19):1419-1429.
[12] Laaksonen R,Ekroos K,Sysi-Aho M,et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J,2016,37(25):1967-1976.
[13] Tarasov K,Ekroos K,Suoniemi M,et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency[J]. J Clin Endocrinol Metab,2014,99(1):E45-E52.
[14] Sachdeva A,Cannon CP,Deedwania PC,et al. Lipid levels in patients hospitalized with coronary artery disease:an analysis of 136,905 hospitalizations in Get With The Guidelines[J]. Am Heart J,2009,157(1):111-117.e2.
[15] Olsson AG,Schwartz GG,Szarek M,et al. High-density lipoprotein,but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome:results from the MIRACL trial[J]. Eur Heart J,2005,26(9):890-896.
[16] Puri R,Nissen S E,Libby P,et al. C-reactive protein,but not low-density lipoprotein cholesterol levels,associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy[J]. Circulation,2013,128(22):2395-2403.
[17] Hilvo M,Meikle PJ,Pedersen ER,et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients[J]. Eur Heart J,2020,41(3):371-380.
[18] Mundra PA,Barlow CK,Nestel PJ,et al. Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention[J]. JCI Insight,2018,3(17):e121326.
[19] Leiherer A,Mundlein A,Laaksonen R,et al. Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients[J]. Eur J Prev Cardiol,2022,29(6):947-956.
[20] Poss AM,Maschek JA,Cox JE,et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease[J]. J Clin Invest,2020,130(3):1363-1376.
[21] Keys A,Menotti A,Karvonen MJ,et al. The diet and 15-year death rate in the seven countries study[J]. Am J Epidemiol,1986,124(6):903-915.
[22] Castelli WP,Anderson K,Wilson PW,et al. Lipids and risk of coronary heart disease. The Framingham Study[J]. Ann Epidemiol,1992,2(1-2):23-28.
[23] Authors/Task Force Members,Committee for Practice Guidelines (CPG),ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Atherosclerosis,2019,290:140-205.
[24] Mortensen MB,Falk E. Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention[J]. Eur Heart J,2017,38(29):2259-2263.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(9):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(9):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(9):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(9):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]